April 2026 Research Update

This month included one human trial testing a practical way to improve exercise capacity and two studies focused on how to measure frataxin in the body as a research marker. Together, these studies point in a consistent direction: short-term cardiopulmonary fitness can be measured and may improve with a structured approach, and frataxin levels measured outside the nervous system may help track biology in studies. The studies do not answer whether these measures translate into slower day-to-day symptom progression, but they help clarify what can be measured reliably in people with Friedreich ataxia (FA). [1] [2] [3]

In a 12-week randomized trial, the combination of nicotinamide riboside (a vitamin B3-related supplement) plus a home exercise program increased peak VO2 (a measure of fitness during exercise testing) more than the control condition. Exercise alone showed a non-significant trend compared with control, and nicotinamide riboside alone was not significantly different from control. This pattern makes the exercise program look like the main driver of the change, while the added value of nicotinamide riboside remains uncertain in this short study. [1]

Safety reporting in the same trial described only mild or moderate side effects across groups, including issues like stomach symptoms and falls. Moderate events were not higher in the combined nicotinamide riboside plus exercise group than in control. This helps put the fitness findings into context as a measured, supervised research program rather than a report of unexpected harms. [1]

Two other studies addressed a different but related question: can frataxin measured in easier-to-access samples reflect what is happening in harder-to-reach tissues? One study measuring nomlabofusp-derived frataxin (hFXN) reported consistent correlations between target tissues (like heart, muscle, and nervous system tissues) and more accessible samples such as skin, cheek (buccal) cells, and platelets, across several animal species and also in people with FA. Another study using two human cohorts reported that peripheral frataxin levels helped predict important long-term clinical milestones in modeling, and carriers tended to have intermediate frataxin levels. [2] [3]

In the modelling study, GAA1 repeat length appeared as a major factor tied to frataxin levels and to clinical function. In plain terms, this reinforces that the underlying genetics are strongly linked to how much frataxin is measurable in the body, and that frataxin measurements may be useful for tracking disease biology in research and trials. What is still not established here is how best to use these measurements for individual predictions, or how changes in frataxin over time relate to changes a person feels day to day. [3] [2]

For patients and caregivers, the main near-term takeaway is that researchers are getting better at measuring things that matter in studies: physical fitness on exercise testing, and frataxin levels in samples like blood, skin, or cheek cells. The 12-week trial result is an early, controlled signal that a supervised home exercise program (with or without nicotinamide riboside) can move a fitness measure in the right direction, but it does not tell us whether walking, balance, speech, or daily function improve over longer timeframes. The frataxin studies mainly matter for research because they support using more accessible samples to monitor frataxin exposure or levels, which could make future studies easier to run and easier to participate in. [1] [2] [3]

What remains uncertain is how these study measures connect to lived experience over time, and whether changes in frataxin measured in peripheral samples reliably mirror changes in the nervous system in everyday settings. Even with those gaps, this month helps clarify two building blocks for future progress: researchers can test interventions against objective fitness outcomes, and they are building stronger evidence that frataxin measurements outside the brain and spinal cord can still be informative for monitoring biology in studies. [1] [2] [3]

This month added a clearer picture of how FA affects daily life and how progression can be tracked over time, with results that point in a consistent direction. Interviews highlighted that balance, speech, coordination, and falls are central day-to-day problems, and caregivers described substantial support needs. A separate 30-month follow-up study reinforced that some clinical scales steadily worsen while others may stay relatively stable, and that baseline severity and GAA1 repeat length help predict who progresses faster. [4] [5]

In qualitative interviews with 20 people with FA and 11 caregivers, patients commonly described neurological symptoms such as impaired speech and loss of balance, and many reported impacts on walking and dressing. Caregivers often reported observing falls and needing to help with personal care and hygiene, and patients rated multiple types of burden as high on a 9-point scale. This helps quantify something many families already know: day-to-day function and safety are major parts of the burden, not just test scores. [4]

In a 30-month follow-up study of 25 people with FA, several commonly used rating scales worsened over time, including measures of ataxia severity and daily activities. Other performance-based measures stayed more stable over the same period. This mix matters because it suggests that different tests may capture different parts of change, and some measures may be less sensitive to progression in certain time windows. [5]

The same longitudinal study found that GAA1 repeat length and baseline SARA score were the strongest predictors of progression, while frataxin levels measured in fibroblasts tracked with GAA1 and baseline severity. In contrast, a spinal fluid marker of nerve injury (CSF NfL) did not predict progression in this group and tended to be higher in younger patients and lower with age. In plain language, not every blood or spinal fluid marker that seems biologically relevant turns out to be useful for predicting near-term change. [5]

For patients and caregivers, these studies mostly add understanding rather than changing anything immediately. The interviews put numbers and shared language around common challenges like walking, dressing, hygiene, and falls, and they highlight how much time caregiving can take. The progression study helps explain why two people with FA can change at different speeds, and why research studies may choose particular scales depending on what kind of change they are trying to detect. [4] [5]

Uncertainty remains about which biomarkers will best forecast day-to-day change for an individual person, and the spinal fluid marker studied here did not perform as a progression predictor over 30 months. Even so, this month made it clearer that baseline severity and the underlying genetics (GAA1 length) are repeatedly important when researchers try to model progression. That helps set expectations for why studies often focus on these factors when they interpret results. [5]

One study this month suggests that difficulty hearing speech in noisy settings can be measured in FA in a way that relates to disease severity. People with FA performed worse than controls on a listening-in-noise test, and scores tracked moderately with a neurological severity exam. This adds to the picture that FA can affect more than balance and movement, and that listening challenges may be part of the overall disease burden for some people. [6]

In 101 people with FA and 38 controls, the control group scored better on all parts of the listening-in-noise test. Test results had moderate correlations with the Friedreich Ataxia Rating Scale exam and weaker correlations with genetics and disease duration. People who already had auditory complaints showed slightly greater impairment on the test. [6]

Age also influenced some parts of the listening test results, which matters because it suggests that listening performance reflects a mix of FA-related factors and general aging effects. In plain language, a single score may not mean the same thing for every person, and researchers may need to account for age when using this kind of test in studies. [6]

For patients and caregivers, this study mainly matters as recognition and measurement: it supports that listening in noisy environments can be a real, measurable issue in FA and may relate to overall disease severity. It does not establish what causes the listening differences in each individual, and it does not test treatments. Still, having a test that picks up these difficulties could help future studies track symptoms that affect conversations, school, and work. [6]

What remains uncertain is how listening-in-noise scores change over time for the same person, since this was a one-time comparison. It is also unclear how strongly these test scores match everyday communication challenges in all settings. This month nonetheless helps clarify that hearing-related function is a measurable part of FA that can be studied alongside movement and daily activity measures. [6]

Several lab and computational studies this month explored how frataxin loss disrupts cells and what kinds of interventions might raise frataxin or protect neurons, but these results are not yet patient treatments. The common pattern is that researchers are identifying specific molecular "handles" that can change frataxin gene activity or reduce certain kinds of cell stress, while also seeing that fixing one part of the problem may not fix everything. These studies add to the longer-term map of what might be targetable, but they do not show clinical benefit. [7] [8] [9] [10]

One cell-based study showed that recruiting a protein called BRD4 to the silenced FXN gene could restart FXN transcription even while repressive chromatin marks remained present. Epigenetic drugs further increased FXN expression in this system, even though repressive marks also increased, highlighting that gene regulation can behave in unexpected ways in FA models. In plain terms, this suggests it may be possible to turn the gene back on without fully removing the "off" signals, at least in lab models. [7]

In neurons grown from an FA mouse model, 7,8-dihydroxyflavone (7,8-DHF), a drug-like compound that activates a brain growth factor receptor (TRKB), reduced markers of DNA damage and programmed cell death. However, it did not restore mitochondrial problems or reduce overall cell death in this model. This mixed result matters because it suggests partial protection is possible, but it also shows that stopping neurodegeneration may require addressing multiple types of cell injury. [8]

A fruit fly FA model study reported that exposure to a very low magnetic field changed iron and sulfur balance in a tissue-specific way and increased oxidative stress in the brain. It also found changes in gene activity related to iron metabolism and oxidative stress pathways. This does not show that magnetic fields affect people with FA, but it helps clarify how frataxin deficiency can create metabolic vulnerability in a living organism model. [9]

A computational study explored predicted targets of compounds found in lavender and rose essential oils across multiple brain disorders, including FA, and highlighted two predicted hub targets (CHRM2 and NR1H3). Computer docking suggested some compounds could fit these targets, and the analysis pointed to pathways related to cholinergic signaling, lipid metabolism, and inflammation. This is a hypothesis-generating step only, because it does not measure effects in people or even in disease models. [10]

For patients and caregivers, these studies are best understood as early-stage research that may matter later if confirmed. They add clarity about possible ways to raise FXN gene activity in cells, and about types of stress that frataxin-deficient neurons and organisms may be vulnerable to. None of these studies tested whether symptoms improve in people, and they should not be read as evidence that a specific supplement, essential oil, or lab compound helps FA. [7] [8] [9] [10]

What remains uncertain is which of these lab signals will translate into safe and meaningful changes in humans, and whether partially improving one pathway (like reducing some cell-death markers) can produce lasting protection. Even with that uncertainty, this month helps clarify that FA biology can be influenced at several points, including how the FXN gene is turned on and how cells respond to stress. That kind of mapping is often the groundwork needed before human trials can be designed. [7] [8] [9] [10]